logo-loader
viewCardiol Therapeutics

Cardiol Therapeutics shares positive new study results supporting lead drug’s ability to protect against heart failure

The study found that Cardiol's cannabidiol formulation reduced myocyte hypertrophy, inflammation, and fibrosis

Cardiol Therapeutics - Cardiol Therapeutics shares positive new study results supporting lead drug’s ability to protect against heart failure
The positive data supports the firm’s plans for its Phase 2 trial looking at acute myocarditis

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) announced positive results from a new study that highlighted its cannabidiol formulation’s ability to combat heart failure.

The study found that Cardiol's cannabidiol formulation significantly reduced myocyte hypertrophy in a model of non-ischemic heart failure.

Additional results showed a dose-dependent reduction of key inflammation markers, decreases in fibrosis, and lower B-type Natriuretic Peptide (BNP) expression, which is widely used to indicate the severity of heart failure.

READ: Cardiol Therapeutics expecting significant growth in 2020 with launch of its pharmaceutical cannabidiol formulation in Canada

Results indicate that Cardiol’s cannabidiol reduced the amount of BNP released, supporting its formulation as a cardioprotective therapy, the Toronto-based company told shareholders.

Cardiol’s cannabidiol formulation, CardiolRx, is a pharmaceutically produced, THC-free (5ppm), highly concentrated product being developed to fight cardiac diseases.

The positive data supports the firm’s plans for its Phase 2 trial looking at acute myocarditis, an inflammatory form of heart failure. The current study results support the anti-inflammatory and anti-fibrotic activity of Cardiol’s cannabidiol formulation when it comes to heart failure.

Data submitted by its research collaborators was showcased at the American College of Cardiology's 69th Annual Scientific Session & Expo together with the World Congress of Cardiology, held virtually from March 28-30.

"The data accepted for presentation at the ACC underscore the importance of Cardiol's research initiatives aimed at developing novel therapeutic strategies to address the devastating consequences of heart failure," stated David Elsley, Cardiol’s CEO.

"The data also support our long-standing view concerning the powerful anti-inflammatory, anti-fibrotic, and cardioprotective properties of pharmaceutically produced cannabidiol, and serve as an encouraging scientific foundation for our planned international trial in acute myocarditis," he added.

Cardiol plans to develop its cannabidiol formulation to treat chronic heart failure, a major healthcare burden in North America, costing the US healthcare system over US$30 billion a year.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Cardiol Therapeutics

Price: 2.64 CAD

TSX:CRDL
Market: TSX
Market Cap: $68.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cardiol Therapeutics signs supply agreement with Medical Cannabis by Shoppers

Cardiol Therapeutics ((TSX: CRDL; OTCQX: CRTPF) CEO David Elsley joined Steve Darling from Proactive to discuss the company announcing a supply agreement with Medical Cannabis by Shoppers.  Elsley discusses what this deal means for the company having a name like Shoppers associated with...

on 19/3/20

2 min read